23 November 2016
: Case report
Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Jiro AbeBDE, Taku SatoB, Ryota TanakaB, Toshimasa OkazakiB, Satomi TakahashiBDOI: 10.12659/AJCR.900941
Am J Case Rep 2016; 17:880-882
Abstract
BACKGROUND: Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy. In the clinical trials of nivolumab, its adverse effects were reported to be less likely than those of conventional anti-cancer agents; however, after practical clinical distribution, it has come to be known that nivolumab induces various immune-related adverse events.
CASE REPORT: A 58-year-old male with a recurrence of lung adenocarcinoma was treated with nivolumab. Only four days after the initial administration of nivolumab, the patient presented with unbearable restlessness and distress that was resistant to all therapeutic agents used, and it gradually became worse. He finally came to need deep sedation despite his cancer status being stable during the course. Clinical tests including magnetic resonance imaging, cerebrospinal fluid cytology, and antibodies of paraneoplastic syndrome exhibited no signs of encephalitis or another possible cause of the neuropathy. The diagnosis of akathisia could be made only by his somatoform presentation. It was uncertain whether or not this complication was correlated with the activation of his immune system.
CONCLUSIONS: Anti-immune check point inhibitors may induce many unknown adverse events. Severe akathisia induced by nivolumab, as in our case, has not been reported yet. Collecting every adverse event of nivolumab may be important to make a better algorithm to manage its huge variety of complications.
Keywords: Akathisia, Drug-Induced
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945910
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945852
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944817
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946074
Most Viewed Current Articles
21 Jun 2024 : Case report
89,036
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,209
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,680
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,688
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030